A novel crosstalk between calcium/calmodulin kinases II and IV regulates cell proliferation in myeloid leukemia cells.

Sara Monaco, Maria Rosaria Rusciano, Angela S Maione, Maria Soprano, Rohini Gomathinayagam, Lance R Todd, Pietro Campiglia, Salvatore Salzano, Lucio Pastore, Eleonora Leggiero, Donald C Wilkerson, Monia Rocco, Carmine Selleri, Guido Iaccarino, Uma Sankar, Maddalena Illario

Journal: Cellular signalling 2015;27(2):204-14

PMID: 25446257

Abstract

CaMKs link transient increases in intracellular Ca(2+) with biological processes. In myeloid leukemia cells, CaMKII, activated by the bcr-abl oncogene, promotes cell proliferation. Inhibition of CaMKII activity restricts cell proliferation, and correlates with growth arrest and differentiation. The mechanism by which the inhibition of CaMKII results in growth arrest and differentiation in myeloid leukemia cells is still unknown. We report that inhibition of CaMKII activity results in an upregulation of CaMKIV mRNA and protein in leukemia cell lines. Conversely, expression of CaMKIV inhibits autophosphorylation and activation of CaMKII, and elicits G0/G1cell cycle arrest,impairing cell proliferation. Furthermore, U937 cells expressing CaMKIV show elevated levels of Cdk inhibitors p27(kip1) and p16(ink4a) and reduced levels of cyclins A, B1 and D1. These findings were also confirmed in the K562 leukemic cell line. The relationship between CaMKII and CaMKIV is also observed in primary acute myeloid leukemia (AML) cells, and it correlates with their immunophenotypic profile. Indeed, immature MO/M1 AML showed increased CaMKIV expression and decreased pCaMKII, whereas highly differentiated M4/M5 AML showed decreased CaMKIV expression and increased pCaMKII levels. Our data reveal a novel cross-talk between CaMKII and CaMKIV and suggest that CaMKII suppresses the expression of CaMKIV to promote leukemia cell proliferation.

Copyright © 2014. Published by Elsevier Inc.

Address: Dipartimento di Scienze Mediche Traslazionali, Federico II University, Naples, Italy.; Department of Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN, USA.; Dipartimento di Scienze Farmaceutiche, Università di Salerno, Fisciano, Salerno,Italy.; Instituto di Endocrinologia ed Oncologia Sperimentale, CNR, Naples, Italy.; CEINGE-Biotecnologie Avanzate, Italy; Dipartimento di Biochimica e Biotecnologie Mediche, Federico II University, Naples, Italy.; CEINGE-Biotecnologie Avanzate, Italy.; Experimental Pharmacology Unit, Department of Research, National Cancer Institute "Fondazione G. Pascale", Napoli, Italy.; Hematology Unit, Azienda Ospedaliera Universitaria "S. Giovanni di Dio e Ruggi d'Aragona", Salerno, Italy.; Department of Medicine, University of Salerno, Italy; IRCCS "Multimedica", Milan, Italy.; Department of Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN, USA. Electronic address: [email protected].; Dipartimento di Scienze Mediche Traslazionali, Federico II University, Naples, Italy. Electronic address: [email protected].
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.